N30 Pharma’s drugs target nitric oxide reductase (NOR), the most important of which is s-nitrosoglutathione reductase (GSNOR) an enzyme of central importance in human health and disease.
GSNOR is a selective enzyme that breaks down s-nitrosoglutathione (GSNO), the most abundant low molecular weight source of the human body’s nitric oxide.
GSNO is of established importance in inflammation, smooth muscle function, receptor function, organ regeneration, vascular hemo-stasis and neuromuscular disease. Inhibition of GSNOR increases the levels of endogenous GSNO, and is a unique therapeutic strategy.
N30 Pharma’s first GSNOR inhibitor entered into human testing in September 2010. Behind this first drug is a robust pipeline of novel GSNOR inhibitor drug candidates.